BioSpace News Archive

VK2809 Treatment Leads to Rapid Reduction in Steatosis, Inflammation and Liver Size in Mouse Model of Glycogen Storage Disease Type Ia (GSD Ia)

In Clinical Trials, BRYHALI Lotion Demonstrated Significant Treatment Success Over Vehicle as Early as Week Two, Which Continued Through Week 12 (Four Weeks Post Treatment)

Protagonist Therapeutics, Inc. today announced that Dr. William J. Sandborn will present clinical data from a Phase 2 study of PTG-100, the Company’s oral, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide that is being developed for treatment of ulcerative colitis, at the United European Gastroenterology Week meeting.

Phase 1 study in patients with chronic rhinosinusitis demonstrated safety and tolerability after 24 weeks of continuous anti-inflammatory treatment with long-acting LYR-210

Verastem, Inc. today announced that the National Comprehensive Cancer Network® (NCCN®) added COPIKTRA™ (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for follicular lymphoma (FL).

More than 300 Property & Casualty and Collision Repair Executives Gather to Hear the Latest Technology Trends and Industry Insights from Mitchell Leaders

Bioiberica confirms, once again, their presence at CPhI Worldwide, the most important event for producers of pharmaceutical ingredients and solutions.

Qatar Biomedical Research Institute (QBRI), a premier research institute under Hamad Bin Khalifa University (HBKU), has signed a collaborative research and training agreement with the Harvard Stem Cell Institute (HSCI) in Boston, USA.

Taros Chemicals GmbH & Co. KG announced the appointment of Dr Torsten Hoffmann as Senior Vice President Drug Discovery.

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS) today announced that its Chief Scientific Officer Christopher G. Twitty, PhD, will give a presentation during the Advances In Immuno-Oncology Congress being held in San Diego, October 11-12.